Peginterferon alfa-2a
Synonym(s)
alfa-2a; alpha-2a; Interferon; Interferon alfa-2a pegylated; peginterferon alpha-2a; peginterferon-alpha-2a; pegylated; pegylated alpha-interferon-2a; pegylated IFN α-2a; pegylated IFN-α-2a; α-2a
DefinitionThis section has been translated automatically.
Synthetic, recombinant interferon alpha derivative. Coupling to polyethylene glycol (PEG) results in delayed degradation and prolonged residence time in the organism (see pegylation below).
IndicationThis section has been translated automatically.
Chronic hepatitis C with elevated transaminases and detectable HCV-RNA in serum, also in patients with compensated liver cirrhosis.
Pregnancy/nursing periodThis section has been translated automatically.
Contraindicated.
Dosage and method of useThis section has been translated automatically.
- Monotherapy: 180 µg 1mal/week s.c.
- Combination therapy with ribavirin (rebetol): 1000 mg p.o. for patients with HCV genotype 1 or 4 < 75 kg bw, 1200 mg for patients > 75 kg bw. 800 mg s.c. for patients with HCV genotype 2 or 3
Undesirable effectsThis section has been translated automatically.
Frequently flu-like general symptoms (fever, fatigue, chills, headaches, myalgia, sweating), reactions at the injection site (erythema)
InteractionsThis section has been translated automatically.
Increase of the plasma level of theophylline.
ContraindicationThis section has been translated automatically.
Allergies to interferons, severe dysfunctions of the liver, autoimmune hepatitis, decompensated liver cirrhosis, severe mental disorders (depression), children < 3 years.
PreparationsThis section has been translated automatically.
Pegasys solution for injection/finished syringe